A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
The purpose of this study is to compare the progression-free survival (PFS) associated with patients treated with erlotinib vs. erlotinib plus cabozantinib. Participants in this study have been diagnosed with EGFR wild-type non-small cell lung cancer (NSCLC). In addition this study will also compare the PFS associated with participants treated with erlotinib vs. cabozantinib.
Back to Clinical Trials list